To determine whether the recovery window (RW) between neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) affects 90-day postoperative morbidity and incidence of lymph node metastasis.
Introduction
Bladder cancer is an aggressive malignancy, with limited treatment options once disease has penetrated the muscle wall of the bladder. With the current treatment standard of radical cystectomy (RC), long-term recurrence-free survival (RFS) and overall survival are 60% and 43%, respectively [1] . The management of bladder cancer is further complicated by the significant morbidity associated with RC. Hence, efforts to maximise cancer outcomes and minimise morbidity for RC patients are essential.
The integration of neoadjuvant cisplatin-based chemotherapy into the treatment plan for muscle-invasive bladder cancer (MIBC) is widely recommended. It has been shown to provide a 5% absolute improvement in survival at 5-years follow-up [2] . Previous studies have shown no difference in perioperative morbidity or mortality with the use of neoadjuvant chemotherapy (NAC) before RC [3, 4] . Conventional wisdom suggests that RC should be delayed for a period after the last dose of NAC to maximise a patient's ability to tolerate surgery. We hypothesise that patients can be safely taken to surgery at earlier times after the last dose of NAC without an increased risk in perioperative morbidity, and that prolonged delays between NAC and RC may risk pathological node metastasis. We reviewed our experience of treatment of high-risk bladder cancer with NAC and RC, to determine whether the timing of RC after NAC affects perioperative morbidity, as well as the risk of nodal metastasis.
Patients and Methods
An Institutional Review Board-approved search was performed of all patients treated with RC for bladder cancer at the University of Texas MD Anderson Cancer Center between January 1995 and December 2013. Patients who received at least one cycle of NAC and had a minimum follow-up of 90-days after RC were included in this study. Exclusion criteria included clinically node-positive disease, metastasis at original presentation, palliative RC, or RC after failed chemo-radiation to the bladder. Patient records were reviewed for demographic, clinical, pathological, and perioperative outcomes.
Clinicopathological parameters collected included age, gender, body mass index (BMI), pre-chemotherapy serum albumin, Eastern Cooperative Oncology Group performance status (ECOG PS), American Society of Anesthesiologists (ASA) score, prior abdominal/pelvic surgical history, prior history of radiotherapy to the abdomen/pelvis, preoperative hydroureteronephrosis, clinical stage, concomitant carcinoma in situ (CIS), variant clinical histology, clinical lymphovascular invasion (LVI), interval (days) between last dose of chemotherapy and surgery (recovery window, RW), preoperative haemoglobin, operative approach, extent of pelvic node dissection, operative time, type of urinary diversion, operative blood transfusion, concomitant procedure, estimated blood loss (EBL), and pathological stage. Patients were staged using the seventh edition 2010 American Joint Committee on Cancer TNM tumour staging guidelines and the 2004 WHO grading classification.
All patients underwent preoperative evaluation, with laboratory studies, chest imaging, abdominal/pelvic crosssectional imaging, examination under anaesthesia (EUA), and transurethral resection (TUR) before starting NAC. All initial and outside resection/biopsy specimens, and final pathological specimens were reviewed by fellowship-trained genitourinary pathologists. Patients who were initially diagnosed at an outside hospital underwent repeat TUR and EUA for further staging information and to assure thorough resection before receiving NAC. All patients included in the analysis were ≤cT 4 N 0 M 0 . Patients with high-risk clinical features including, cT [3] [4] , hydroureteronephrosis, LVI, and variant histology were referred to the medical oncology service for NAC. Nineteen different chemotherapy combinations were used during the evaluation period. The most commonly used combinations included: (i/ii) dose-dense/standard methotrexate, vinblastine, doxorubicin and cisplatin (MVAC); (iii) gemcitabine cisplatin; (iv) ifosfamide, doxorubicin, gemcitabine; or (v) cisplatin, gemcitabine, ifosfamide. All regimens were administered as previously described [3, [5] [6] [7] . For the purpose of our analysis patients were stratified by the use of a cisplatin-based regimen, and the number of chemotherapy cycles was recorded. Both variables were included in our generalised linear model to determine their effect on our endpoints. All RCs were performed by fellowship-trained urological oncologists. Limits of standard pelvic lymph node dissection included the bifurcation of the common iliac artery proximally, the bladder medially, and the genitofemoral nerve laterally. Extended node dissection included the standard template plus the presacral nodes and proximal extension up to the aortic bifurcation. Patient medical records were carefully reviewed to capture all 90-day postoperative complications and re-admissions. Patients who died within 90-days of RC were listed as mortality from surgery. All complications were classified by the Clavien-Dindo system [8] . Complications were categorised using the system previous published by Shabsigh et al. [9] , we used the same definition for postoperative ileus/small bowel obstruction and constipation.
The distribution of days between NAC and RC ranged from18-199 over our study period, with a median recovery period of 46 days (6.5 weeks). To better characterise perioperative morbidity and incidence of nodal metastasis for patients with various recovery periods, as well as those with prolonged delays (>12 weeks), patients were stratified into four RWs by 21-day intervals (18-42; 43-63; 64-84; ≥85 days), from their last day of NAC to the day of RC. Clinical characteristics were compared using one-way ANOVA or Kruskal-Wallis and the Pearson chi-squared test (or Fisher's exact test). Univariable and multivariable generalised linear models were used to evaluate variables associated with 90-day morbidity, major complications (Clavien-Dindo Grade ≥III), and re-admission. A separate model was used to determine clinical variables associated with pathological lymph node involvement. All models were performed using a stepwise forward elimination method. Variables with a P < 0.20 from the univariable analysis were included in the full multivariable model that included the four RWs. Variables with a P < 0.05 in the full model and the four RWs were placed in the final multivariable model. A P < 0.05 was considered statistically significant. All statistical analysis was performed using STATA/SE version 13.1 statistical software (Stata Corp. LP, College Station, TX, USA).
Results
A total of 338 patients met our inclusion criteria. Clinicopathological characteristics and the perioperative complications for the entire cohort of 338 patients are listed in Table 1 . There were 130 (38%) patients that had a minor complication and 70 (20%) patients that had a major complication after RC (Table 2 ). Gastrointestinal problems were the most common type of complication after RC, Table 1 . There was a significant age difference between the cohorts (P = 0.002), with patients with a RW of 64-84 days having the highest median age (70 years). A dose-dense NAC regimen was most frequently used in patients with a RW of 18-42 days (33%), and least frequently used in patients with an RW ≥85 days (4%). The mean preoperative serum haemoglobin was lowest in patients in the earliest RW, with a value of 10.8 mg/dL, and highest in patients in with a RW ≥85 days (11.8 mg/dL).
There was no difference in operative time, EBL, or the need for blood transfusion amongst the four RWs. The creation of a continent urinary diversion at the time of surgery was most common in the early RWs (30.2%), whilst patients who had a RW of ≥85 days had the lowest rate of continent diversion creation (11.2%). The incidence of extravesical disease (pT [3] [4] at the time of RC was lower in the RWs of 18-42, and 43-63 days, although this was not found to be statistically significant (P = 0.109; Table 3 ).
There was no difference in re-admission incidence amongst the four RWs. In the univariable analysis only prolonged operative time (≥420 min) was significantly associated with 90-day re-admission (odds ratio [OR] 2.20, 95% CI: 1.26-3.82; P = 0.005). In the full multivariable model, prolonged surgical duration (OR 2.24, 95% CI: 1.26-3.98; P = 0.006) continued to be an independent predictor for 90-day readmission, while the RW had no effect on re-admission incidence, in both the univariable and multivariable models (Table 4 ).
There was no difference in overall morbidity amongst the four RWs (P = 0.735). The univariable analysis to determine predictors of morbidity (Grade I-V) found the need for a blood transfusion, the number units of red blood cells (RBCs) transfused, number of nodes removed, and pathological extravesical disease to be associated with overall morbidity (Table 5 ). In the final multivariable model only pathological extravesical disease (OR 1.95, 95% CI: 1.16-3.26; P = 0.011) was an independent predictor of 90-day morbidity.
The incidence of major complications ranged from 15% to 24% across the four RWs, including four patients who died (two from multiple organ dysfunction syndrome and two from cardiac arrest). In the univariable model, age, prolonged surgical duration, significant blood loss (EBL > 1 000 mL), ECOG PS, ASA score, the need for blood transfusion, and the number of transfused units of RBCs were associated with major complications (Table 6 ). In the final multivariable model that included the RWs, both age (OR 1.05, 95% CI: 1.02-1.09; P = 0.004) and prolonged surgical duration (OR 2.87, 95% CI: 1.52-5.42; P = 0.001) were independent predictors of a major complication.
Patients with a RW of 64-84 days had the highest incidence of extravesical disease (56%), while patients with a RW of ≥85 days had the highest incidence of positive lymph nodes (40%). In the univariable analysis clinical stage and a RW of ≥85 days were both associated with lymph node metastasis. In the final multivariable model only a RW of ≥85 days remained an independent predictor of lymph node metastasis (OR 2.92, 95% CI: 1.20-7.09; P = 0.018; Table 7) .
Discussion
Our present study demonstrated that the recovery period (RW) after the last dose of NAC in patients treated with RC for high-risk bladder cancer did not affect perioperative morbidity. Although a recovery period of ≥85 days was associated with an almost three-fold increase risk of nodal metastasis (OR 2.92, 95% CI: 1.20-7.09 P = 0.018). Because of the poor prognosis for patients who are found to have lymph node-positive disease after RC, the recovery period represents a modifiable risk factor that could influence oncological outcomes.
Level 1 evidence has shown that the use of multimodal cisplatin-based chemotherapy followed by RC provides a clinically significant survival benefit compared to RC alone for patients with MIBC [3] . Despite this, widespread implementation of NAC before RC still remains low [10] . In a recent survey of urologists, the delay of RC was the second most common concern influencing whether to recommend NAC, followed by age and comorbidities [11] . Unfortunately, the survival benefits of adjuvant chemotherapy are questionable at best, and as many as 30% of patients may be unable to receive adjuvant therapy due to surgical morbidity [12] . Due to this, multiple efforts have been made to improve the delivery of NAC, including determining the optimal patients for systemic therapy, identifying the optimal regimens, and using dose-intense regimens to shorten the interval to definitive treatment [13] [14] [15] . We sought to further improve upon the delivery of multimodal treatment by identifying the effects of early RC after NAC on perioperative morbidity, as well as determining the association between timing of RC after NAC and the incidence of nodal metastases.
We were able to show that early (≤42 days) RC can be performed safely without an increased risk of morbidity, major complications or re-admission. In our multivariable analysis, the only independent predictor of any complication was pathological extravesical disease (≥pT3). Thus, patients at risk of extravesical disease or who fail to respond to NAC require additional counselling regarding possible increased morbidity with surgery. Age and an operative time >7 h were found to be predictors of a major complication. In our present cohort, the multivariable analysis showed a 5% increased risk of a Clavien-Dindo Grade ≥III complication with every year increase in age. Age is frequently recognised as a predictive factor for overall morbidity, as well as major complications [9, 16, 17] . Prolonged operative time was also found to be the only predictor of 90-day re-admission.
Patients with surgical durations >7 h were more likely to be undergoing a concomitant procedure, a continent urinary diversion, and had higher intraoperative blood loss compared to patients with surgical durations of <7 h. During a lengthy open RC, patients experience increased atmospheric exposure and manipulation of the bowel, and an extended period in a flexed Trendelenburg position, all of which may have significant bearings on gastrointestinal activity, and cardiopulmonary recovery after surgery.
In the full multivariable model for nodal metastasis only a RW of ≥85 days was found to be an independent predictor, resulting in an almost three-fold increased risk of nodal involvement. Historically, patients with nodal metastasis at the time RC have been shown to have a 5-year RFS ranging from 35% to 40% [1, 18] . Those patients found to have nodal metastasis at the time of RC after preoperative chemotherapy have an even worse prognosis, with a 2-year RFS of <15% [19] . Despite our present finding of a RW of ≥85 days being the strongest predictor of nodal metastasis, other clinicopathological features have been found to be associated with lymph node positivity and more advanced stage, including: LVI, hydroureteronephrosis, and advanced clinical stage (cT 3-4 ) [20] [21] [22] [23] [24] . Because of the dismal prognostic outcomes for patients with nodal involvement, we believe that a delay in RC of ≥85 days after NAC may compromise patient survival. Hence, recovery time between NAC and RC may represent a modifiable risk factor, which may potentially affect oncological outcomes. In a previous evaluation of 153 patients treated with NAC and RC, Alva et al. [25] found that timing of RC between 4 and 12 weeks did not affect overall or disease-specific survival. Their cohort included only a few patients who had delays of >10 weeks and even fewer of >12 weeks. Hence, their evaluation of this group of patients is limited. In another retrospective study that evaluated timing of RC after initial diagnosis in a national data set, Gore et al. [26] assessed survival outcomes in 155 patients who underwent RC at >12 weeks after diagnosis to 193 patients treated with RC at <12 weeks. The authors found that patients treated with RC at >12 weeks after diagnosis had twice the hazard (hazard ratio 2.01; P = 0.003) of death from bladder cancer compared to patients who underwent RC at <12 weeks. Although their study cohort did not receive NAC, the analysis also reveals the importance of the effect of timing of definitive surgical treatment on oncological outcomes. As with our present analysis the 12-week (>84 days) time period appears to be a significantly associated with outcomes.
In our present study, the size of the cohort with a RW of ≥85 days was less than the other treatment intervals, although this is a reflection of our normal clinical practice. In our present cohort, 41% of patients underwent RC within 6 weeks (18-42 days), including 25 patients who had surgery in <4 weeks. Five patients underwent RC within 3 weeks from their last dose of NAC, and two of the five had a complication, one of the five had a major complication, and none of the patients had a re-admission in the 90-day followup period. Because of the retrospective nature of the present study, we were unable to accurately determine the reasons for differences in recovery periods for each patient between their last dose of NAC and RC. Scheduling delays appeared to be a common cause for delay to RC after the last dose of NAC, and represents a modifiable factor that can be reduced by the urologist and medical oncologist. The primary reason for scheduling delays in our present cohort was from having NAC administered at an outside institution, followed by the need for preoperative cardiac clearance. In addition, as a tertiary cancer centre, a large proportion of our patient population reside in a different county or State. Hence, the need to travel might also have been a contributing factor to delays in definitive treatment.
To reduce scheduling delays, our recommendation for best practice involves coordinating with the medical oncologist to determine the appropriate date for RC during the initial consultation visit. Ideally, patients should be quickly seen by an oncologist within 5-7 days following re-staging or initial staging by their urologist. Direct communication with the medical oncologist may facilitate initial evaluation, as well as initiation of systemic treatment. The importance of early initiation of chemotherapy and timely RC after NAC should be discussed with the patient to help minimise delays. Once the NAC regimen and number of cycles are determined, communication with the planned surgeon should ensue to determine optimal time for possible re-staging studies (CT, EUA, and cystoscopy) and RC. The expected recovery time from NAC, based on patient age and comorbidities, as well as the need for cardiac clearance before surgery, should be factored into the decision of the planned surgical date. Open communication between all providers (oncologist, urologist, and cardiologist/internist) is required during the prechemotherapy visits for efficient treatment planning. After the visit with the oncologist, NAC should be started within 1 week. Patients should be closely monitored during NAC and proceed with RC once performance status has recovered. Based on our present results there is no difference in the risk of perioperative morbidity when RC is performed within 6 weeks or from 6 to 12 weeks from the last dose of NAC, although a surgical date after 12 weeks, was associated with an increased risk of nodal metastasis.
The findings in our present evaluation are limited by all the inherent weaknesses of a retrospective study. Toxicity grading from chemotherapy, or reasons for delay to RC after NAC The models use stepwise forward elimination methods with a P < 0.05 as the significance level for removal from the model and keeping 'Interval between NAC and RC' in the model.
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© 2018 The Authors BJU International © 2018 BJU International were not able to be accurately assessed retrospectively from patient records, particularly from patients who received a portion of their systemic therapy at an outside facility. Despite follow-up at our institution, postoperative complications managed outside of our institution may not have been captured in our review. Also, there were multiple chemotherapy regimens used in our present cohort. Each regimen may have different effects on patient performance status recovery before RC. Our present results also represent patients treated at a high-volume tertiary cancer centre and, hence the perioperative outcomes may not be transferrable to a general community practice. Socioeconomic status was not captured for analysis and may play a role in the timing of RC after NAC. Because of the limitations of cross-sectional imaging, up to 24% of patients with clinical lymph nodenegative disease have been found to have lymph nodepositive disease after RC [1] . Therefore, a subset of patients found to have pN1 disease in the RW of ≥85 days cohort, may possibly represent disease that was not identified on initial clinical staging. In addition, our present analysis does not assess perioperative outcomes in patients who were treated with RC alone; hence no comparisons can be made between patients treated with NAC and RC. Previous studies have shown no difference in morbidity or operative times with the use of NAC. In the first prospective trial comparing NAC and RC vs RC alone, Grossman et al. [3] found no difference in postoperative morbidity or mortality between the two groups. In the largest retrospective study evaluating morbidity after RC, which evaluated 1 142 patients undergoing RC including 132 (12%) who received preoperative chemotherapy, the use of NAC was not found to be predictive of minor or major complications after RC [9] In addition, retrospective analysis of large contemporary population-based databases have not found NAC to increase the risk of complications or death after RC [4, 27] . Operative times between patients treated with NAC and RC vs RC alone was assessed in a randomised prospective trial by Kitamura et al. [28] , which evaluated 65 patients in the RCalone group and 59 patients in the NAC and RC group. The authors found no difference in the median operative times between the two groups (456 vs 460 min; P = 0.60). We hope our present results help to eradicate the dogma that prolonged recovery is needed between NAC and RC, as well as encourage urologists and oncologist to recognise current barriers in their own practice that result in delays in definitive treatment. The models use stepwise forward elimination methods with a P < 0.05 as the significance level for removal from the model and keeping 'Interval between NAC and RC' in the model. The models use stepwise forward elimination methods with a P < 0.05 as the significance level for removal from the model and keeping 'Interval between NAC and RC' in the model. The models use stepwise forward elimination methods with a P < 0.05 as the significance level for removal from the model and keeping 'Interval between NAC and RC' in the model.
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Conclusion
Patients can safely undergo RC from 2.5-12 weeks (18-84 days) after completing NAC without any difference in risk of perioperative morbidity. Delaying RC beyond 12 weeks after completing NAC was associated with an increase in the risk of nodal metastasis, which may compromise patient survival. Efforts should be made to limit surgery delays and proceed with definitive treatment once performance status has recovered.
